178 related articles for article (PubMed ID: 25139313)
1. Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.
Zafar MA; Droege C; Foertsch M; Panos RJ
Expert Opin Investig Drugs; 2014 Dec; 23(12):1687-701. PubMed ID: 25139313
[TBL] [Abstract][Full Text] [Related]
2. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.
Malerba M; Radaeli A; Montuschi P; Babu KS; Morjaria JB
Expert Opin Investig Drugs; 2017 Mar; 26(3):319-329. PubMed ID: 28117615
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.
Malerba M; Radaeli A; Morjaria JB
Drug Discov Today; 2012 May; 17(9-10):496-504. PubMed ID: 22119310
[TBL] [Abstract][Full Text] [Related]
4. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
Monaco TJ; Hanania NA
Expert Opin Emerg Drugs; 2017 Sep; 22(3):285-299. PubMed ID: 28868931
[TBL] [Abstract][Full Text] [Related]
5. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
Tashkin DP; Fabbri LM
Respir Res; 2010 Oct; 11(1):149. PubMed ID: 21034447
[TBL] [Abstract][Full Text] [Related]
6. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
Melani AS
Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
[TBL] [Abstract][Full Text] [Related]
7. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
Beeh KM; Beier J
Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
[TBL] [Abstract][Full Text] [Related]
8. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
9. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.
Loh CH; Donohue JF; Ohar JA
Expert Opin Drug Saf; 2015 Mar; 14(3):463-72. PubMed ID: 25563342
[TBL] [Abstract][Full Text] [Related]
10. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
Matera MG; Cazzola M
Drugs; 2007; 67(4):503-15. PubMed ID: 17352511
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
Calzetta L; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
[TBL] [Abstract][Full Text] [Related]
12. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
13. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
15. [Medication of the month. Indacaterol (Onbrez Breezhaler) and chronic obstructive pulmonary disease].
Corhay JL; Louis R
Rev Med Liege; 2011 Sep; 66(9):498-502. PubMed ID: 21995240
[TBL] [Abstract][Full Text] [Related]
16. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
Kume H
Nihon Rinsho; 2016 May; 74(5):813-9. PubMed ID: 27254952
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and therapeutics of bronchodilators.
Cazzola M; Page CP; Calzetta L; Matera MG
Pharmacol Rev; 2012 Jul; 64(3):450-504. PubMed ID: 22611179
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
19. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
Kerwin EM; Williams J
Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
[TBL] [Abstract][Full Text] [Related]
20. An update on the use of indacaterol in patients with COPD.
Brienza NS; Amor-Carro O; Ramos-Barbón D
Ther Adv Respir Dis; 2011 Feb; 5(1):29-40. PubMed ID: 21059700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
